Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
HCWB | US
-0.03
-4.43%
Healthcare
Biotechnology
30/06/2024
09/03/2026
0.59
0.62
0.63
0.55
HCW Biologics Inc. a clinical-stage biopharmaceutical company focuses on discovering and developing novel immunotherapies for chronic low-grade inflammation and age-related diseases. The company's lead products include HCW9218 which is an injectable immunotherapeutic for patients with pancreatic ovarian breast prostate and colorectal cancers as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases such as alopecia areata and metabolic diseases. It also develops HCW9201 a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar Florida.
View LessLow Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
115.8%1 month
128.2%3 months
110.1%6 months
149.7%-
-
2.80
-1.59
0.37
-3.63
7.66
-
-36.58M
25.86M
25.86M
-
-2.24K
-
-0.60
-344.32
0.87
0.14
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.29
Range1M
0.62
Range3M
1.67
Rel. volume
0.13
Price X volume
12.69K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| PolyPid Ltd | PYPD | Biotechnology | 4.18 | 28.44M | -0.24% | n/a | 689.01% |
| CELU | CELU | Biotechnology | 1.25 | 27.48M | 3.31% | n/a | 127.38% |
| INmune Bio Inc | INMB | Biotechnology | 1.31 | 25.98M | -1.50% | n/a | 14.65% |
| PDS Biotechnology Corporation | PDSB | Biotechnology | 0.6851 | 25.23M | 1.81% | n/a | 78.85% |
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 4.08 | 24.87M | -10.33% | n/a | 0.00% |
| Enlivex Therapeutics Ltd | ENLV | Biotechnology | 1.16 | 24.83M | 1.75% | n/a | 2.92% |
| Xilio Therapeutics Inc. Common Stock | XLO | Biotechnology | 0.54 | 23.73M | 1.89% | n/a | 25.98% |
| Dyadic International Inc | DYAI | Biotechnology | 0.8 | 23.58M | 4.22% | n/a | 175.64% |
| Edesa Biotech Inc | EDSA | Biotechnology | 7.14 | 23.19M | 9.51% | n/a | 1.35% |
| iBio Inc | IBIO | Biotechnology | 2.5 | 22.84M | -4.21% | n/a | 20.92% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6001 | 11.60M | -5.42% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.98 | 6.06M | -4.33% | n/a | 204.46% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.47 | 3.75M | -0.67% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.39 | 3.71M | -1.76% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.63 | 0.53 | Cheaper |
| Ent. to Revenue | 7.66 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.80 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 110.13 | 72.80 | Riskier |
| Debt to Equity | -1.59 | -1.23 | Cheaper |
| Debt to Assets | 0.37 | 0.25 | Expensive |
| Market Cap | 25.86M | 3.66B | Emerging |